Last reviewed · How we verify

Lenalidomide, dexamethasone — Competitive Intelligence Brief

Lenalidomide, dexamethasone (Lenalidomide, dexamethasone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunomodulatory agent + corticosteroid. Area: Oncology.

phase 3 Immunomodulatory agent + corticosteroid Cereblon (CRBN); glucocorticoid receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Lenalidomide, dexamethasone (Lenalidomide, dexamethasone) — IRCCS Centro di Riferimento Oncologico della Basilicata. Lenalidomide enhances immune cell proliferation and anti-tumor activity while dexamethasone provides anti-inflammatory and immunomodulatory effects to treat multiple myeloma.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Lenalidomide, dexamethasone TARGET Lenalidomide, dexamethasone IRCCS Centro di Riferimento Oncologico della Basilicata phase 3 Immunomodulatory agent + corticosteroid Cereblon (CRBN); glucocorticoid receptor
VRD for first-cycle induction therapy VRD for first-cycle induction therapy The First Affiliated Hospital of Soochow University marketed Proteasome inhibitor + immunomodulatory agent + corticosteroid combination 26S proteasome (bortezomib); cereblon/CRBN (lenalidomide); glucocorticoid receptor (dexamethasone)
PAD combination PAD combination Cooperative Study Group A for Hematology marketed Combination therapy (proteasome inhibitor + immunomodulatory agent + corticosteroid) 26S proteasome; cereblon (CRBN); glucocorticoid receptor
Drug: Carfilzomib + Lenalidomide + Dexamethasone Drug: Carfilzomib + Lenalidomide + Dexamethasone Amgen marketed Proteasome inhibitor + Immunomodulatory agent + Corticosteroid combination 20S proteasome (carfilzomib); cereblon/CRBN (lenalidomide); glucocorticoid receptor (dexamethasone)
Lenalidomide and low-dose dexamethasone Lenalidomide and low-dose dexamethasone Celgene phase 3 Immunomodulatory agent + corticosteroid Cereblon (CRBN), TNF-α pathway; glucocorticoid receptor
Bortezomib/Lenalidomide/ Low dose Dex Bortezomib/Lenalidomide/ Low dose Dex King Faisal Specialist Hospital & Research Center phase 3 Proteasome inhibitor + Immunomodulatory agent + Corticosteroid combination Proteasome (bortezomib); Cereblon (lenalidomide); Glucocorticoid receptor (dexamethasone)
Lenalidomide, Dexamethasone, PBSCT Lenalidomide, Dexamethasone, PBSCT Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH phase 3 Immunomodulatory agent + corticosteroid + stem cell transplantation Cereblon (CRBN), TNF-α, IL-2, glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunomodulatory agent + corticosteroid class)

  1. Celgene · 1 drug in this class
  2. IRCCS Centro di Riferimento Oncologico della Basilicata · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lenalidomide, dexamethasone — Competitive Intelligence Brief. https://druglandscape.com/ci/lenalidomide-dexamethasone. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: